Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Improving Outcomes in Premature Births: Nitroglycerin Shows Promise for Helping Preterm Infants

27.03.2007
The costs due to complications from preterm birth are staggering. In Canada, outlays for specialized care of surviving preterm infants are estimated to be almost $2 billion per year.

In a 5-year, randomized, placebo-controlled clinical study, researchers found that giving nitroglycerin to mothers who had entered premature labor led to significant improvement in their baby’s health. The results of the study are reported in the January issue of the American Journal of Obstetrics & Gynecology.

In previous studies of drugs to suppress labor contractions to allow the fetus more time to develop in utero, some drugs were able to delay delivery, but none improved the baby’s health outcome. This study is the first to show that the baby benefited from the therapy, especially those who are born very prematurely (at 24 to 28 weeks). Using a composite measure of the newborn’s health including perinatal death, markers of brain damage and serious lung and bowel complications, mothers treated with nitroglycerin had significantly healthier babies.

Graeme N. Smith, MD, PhD, states, “Our team is very excited about these findings. It is estimated that it costs the Canadian health system almost $2 billion a year to take care of premature babies and their medical complications. Given the immeasurable societal and family costs associated with preterm birth and having a sick baby or child, treatment with nitroglycerin may result in major cost saving and longer-term health benefits for these babies.”

In an accompanying editorial, Associate Editor Jay D. Iams, MD, writes about the study, “Their work is notable not only for their interesting results but also for the quality of the study design, execution, and report.” He continues, “Perhaps most importantly, the authors chose neonatal morbidity, a ‘health outcome,’ as the primary endpoint instead of a surrogate such as days gained or percent of births before 32 or 35 weeks of gestation.”

The article is “Randomized double-blind placebo-controlled trial of transdermal nitroglycerin for preterm labor” by Graeme N. Smith, MD, PhD, Mark C. Walker, MD, MSc, Arne Ohlsson, MD, MSc, Karel O’Brien, MD and Rory Windrim, MD, MSc. The editorial is “Transdermal nitroglycerin for preterm labor” by Jay D. Iams, MD. Both appear in the American Journal of Obstetrics & Gynecology, Volume 196, Issue 1 (January 2007) published by Elsevier.

Pamela Poppalardo | alfa
Further information:
http://www.elsevier.com

More articles from Health and Medicine:

nachricht Cells adapt ultra-rapidly to zero gravity
28.02.2017 | Universität Zürich

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Cells adapt ultra-rapidly to zero gravity

28.02.2017 | Health and Medicine

An Atom Trap for Water Dating

28.02.2017 | Earth Sciences

New pop-up strategy inspired by cuts, not folds

27.02.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>